Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

CureDuchenne Ventures

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 17
Average round size
info
The average size of a deal this fund participated in
$45M
Portfolio companies 13
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.24
Exits 5
Key employees 3

Areas of investment

  • Biotechnology
  • Medical
  • Health Care
  • Therapeutics
  • Life Science
Summary

The fund has exact preference in a number of founders of portfolio startups. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Capricor Therapeutics, 4D Molecular Therapeutics, Exonics Therapeutics Among the most successful fund investment fields, there are Medical Device, Genetics.

The top amount of exits for fund were in 2019. The high activity for fund was in 2019. The fund is generally included in less than 2 deals every year. The real fund results show that this Corporate Investor is 30 percentage points more often commits exit comparing to other companies. This CureDuchenne Ventures works on 21 percentage points more the average amount of lead investments comparing to the other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars.

The overall number of key employees were 3.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the CureDuchenne Ventures, startups are often financed by Tavistock Life Sciences, Takeda Pharmaceutical, Moore Venture Partners. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, Logos Capital, Viking Global Investors. In the next rounds fund is usually obtained by The Column Group, National Institutes of Health.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of CureDuchenne Ventures:
Typical Co-investors
CureDuchenne Ventures is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after CureDuchenne Ventures:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Batshit Crazy Ventures Boulder, Colorado, United States
BlueGem Capital Partners England, London, United Kingdom
ChemRar Ltd Khimki, Moscow Oblast, Russia
Clinton Global Initiative New York, New York, United States
Fischer Pharmaceutical Laboratories Ltd Israel, Tel Aviv, Tel Aviv District
Groupe ADP France, Ile-de-France, Paris
Gunosy Chiba, Japan, Minato
Hongrui Touzi China, Jiading, Shanghai
Inner Mongolia Kenuohuagai Investment Management -
Link11 Frankfurt, Germany, Hessen
Nishi-Chugoku Japan, Shimonoseki, Yamaguchi Prefecture
Panorama Point Partners Nebraska, Omaha, United States
Pivotal Group Arizona, Phoenix, United States
Prehype New York, New York, United States
Sipadan Capital, LLC New York, New York, United States
Strata Credit Union Bakersfield, California, United States
Taixiang Investment Management China, Ningbo, Zhejiang
Yifeng Investment China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Code Biotherapeutics

Biotechnology
Life Science
$75M07 Jun 2022 Hatfield, Pennsylvania, United States

Gennao Bio

Biotechnology
Health Care
Life Science
Medical
$1M22 Dec 2021 New York, New York, United States

Pepgen

Biotechnology
Clinical Trials
Medical
$112M05 Aug 2021 Oxford, England, United Kingdom

Code Biotherapeutics

Biotechnology
Life Science
$10M20 Apr 2021 Hatfield, Pennsylvania, United States

Entrada Therapeutics

Biotechnology
Emergency Medicine
Genetics
Health Care
Medical
$116M31 Mar 2021 Boston, Massachusetts, United States

Pepgen

Biotechnology
Clinical Trials
Medical
$45M09 Dec 2020 Oxford, England, United Kingdom

Edgewise Therapeutics

Biopharma
Biotechnology
Health Care
$95M08 Dec 2020 Boulder, Colorado, United States

Biotechnology
Health Care
Medical
Therapeutics
10 Nov 2020 British Columbia

Biotechnology
Therapeutics
$1M23 Apr 2020 Seattle, Washington, United States
News
Entrada Therapeutics Closes $116M Series B Financing

– Entrada Therapeutics from Boston develops intracellular biologics to treat devastating diseases.
– The company closed a $116m Series B financing.
– The round was led by Wellington Management Company and joined by Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment Authority (“QIA”), Moore Strategic Ventures, Goldman Sachs, CureDuchenne Ventures and one undisclosed global investment firm.
– Existing investors 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital also participated in the financing.
– The new investment will be used to advance its pipeline to the clinic.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent CureDuchenne Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: